#1. settling the Biotime HESC IP divestiture will bring share and warrants to existing shareholders.
#2. This statement from press release and what it implies:
"Other investigator-sponsored trials this year could be on hematologic myeloid indications like acute myelogenous leukemia and myelodysplastic syndromes."
AML is a very serious myelogenous cancer that affects the growing elderly population. At present, all people can hope for is chemotherapy followed by a possible bone marrow transplant (tolerable by the young cancer victims we think of at places like St Judes, but not sot much by the elderly). In my opinion/speculation there are investigators out there that would like to attack AML with imetelstat.
I agree meliorist_man. There is a third reason I'm staying, as commented on by both rattllebug and earfool, in that independent researchers continue to start their own studies and I consider that to be very compelling.
Yeah, I agree with your reason three. the IST acronym is being heard a lot these days, especially with regard to GERN. It's the new wave?
Or does it underscore the idea of "proof of concept" with imetelestat in the sense that 'we kinda know what it can do, but don't quite know how to best use it'. (It kind of reminds me of the difference between bacteriocide and bacteriostat, in that a true chemotherapy drug is a -cide and imetelstat behaves more like a -stat. Interesting the name they chose for GRN163L)
Reason # 3 is more IST"s. Agree wholeheartedly.
Reason # 4 could be that in the event of the eternal buy-out speculation actually becoming a reality, we will earn a premium of up to a triple from the current PPS. Buy-out chances go up tremendously after the Biotime deal closes.